B
Bull
Bull · 25%RPTX
$1.12
シナリオ価格
$2.650
+0.020 (+0.76%)終値時点
Loading chart…
- High
- 2.650
- Open
- 2.640
- VWAP
- 2.64
- Vol
- 1.22M
- Mkt Cap
- 143.47M
- Low
- 2.620
- Amount
- 3.22M
- EV/EBITDA, TTM
- 0.00
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
AI analysis of Repare Therapeutics Inc (RPTX)
sellNot a good buy right now. The stock is trading around $2.65 despite an agreed acquisition value cited at ~$1.82/share, which implies unfavorable risk/reward for an impatient buyer: upside is capped unless a higher bid emerges, while deal-close at the stated terms would imply meaningful downside from current levels. With no proprietary buy signals today and technicals showing overbought conditions near resistance, this is an avoid/sell setup rather than a fresh entry.
バリュエーション指標
The current forward P/E ratio for Repare Therapeutics Inc (RPTX) is -2.69, compared to its 5-year average forward P/E of -4.22.
Alphio AI Price Scenarios for RPTX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding RPTX
イベントタイムライン
ニュース
7.512-26NASDAQ.COMGalectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
2.012-24NASDAQ.COMRepare Therapeutics Surges 18.9% Leading Biotechnology Sector Gains
8.512-24NASDAQ.COMRepare Therapeutics Acquires Gilead's RP-3467 for Up to $30 Million
8.512-24BenzingaGilead Acquires Repare Therapeutics' RP-3467 for Up to $30 Million
8.512-18PRnewswireHalper Sadeh Investigates United Security Bancshares Acquisition by Community West
RPTX FAQ — answered by Alphio AI
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Not a good buy right now. The stock is trading around $2.65 despite an agreed acquisition value cited at ~$1.82/share, which implies unfavorable risk/reward for an impatient buyer: upside is capped unless a higher bid emerges, while deal-close at the stated terms would imply meaningful downside from current levels. With no proprietary buy signals today and technicals showing overbought conditions near resistance, this is an avoid/sell setup rather than a fresh entry.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。